Novel Strategies for Immunotherapy in HER2-/HR+ Metastatic Breast Cancer: Insights from GBCC 2024 Presentation
Professor Ji-Hyeon Kim (Department of Hematology-Oncology) at Seoul National University Bundang Hospital gave a presentation on the effectiveness of cancer immunotherapy in HER2-/HR+ metastatic breast cancer at the World Breast Cancer Congress (GBCC 2024) held from 25th to 27th. [메디칼업저버 양영구 기자] Expectations are growing that immunotherapy drugs may be used as a treatment option […]
Keytruda Extends Life in Renal Cell Carcinoma Study, While Opdivo Falls Short
At the American Society of Clinical Oncology’s Genitourinary Cancer Symposium on the 27th (local time), Keytruda shared successful overall survival results in renal cell carcinoma, while Opdivo presented results that failed to reach statistical significance. The picture is an image that represents the kidneys. © Adobe Stock MSD’s Keytruda extended life for patients after renal […]
MSD Korea Announces Approval of Keytruda for First-Line Treatment of HER2-Positive Gastric Cancer
MSD Korea held a press conference on the 16th to commemorate the domestic approval of Keytruda (ingredient pembrolizumab) for the first-line treatment indication for HER2-positive advanced gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma. / Photo = Reporter Hwang Jae-seon Keytruda combination therapy was introduced as a new treatment option that demonstrated clinical benefits beyond the […]
MSD Korea Advocates for Expanding Insurance Coverage for Keytruda in Women’s Cancer Indications
MSD Korea Advocates for Expanded Insurance Coverage for Keytruda Indications in Women’s Cancer MSD Korea recently hosted a thought-provoking ‘Women’s Cancer Media Seminar’ on the 27th, shedding light on the urgent need to widen insurance standards for Keytruda, the groundbreaking ingredient pembrolizumab. Last June, a formal request was submitted for a thorough review aimed at […]
Opdivo + Yervoy Combination Therapy Improves Long-Term Survival in Lung Cancer Patients, Reveals WCLC 2023 Keytruda + Chemotherapy Demonstrates Long-Term Survival Benefit for Metastatic Lung Cancer, Reports WCLC 2023
The World Lung Cancer Society International Conference (WCLC 2023) is currently taking place in Singapore from the 9th to the 12th, focusing on the latest advancements in the treatment of non-small cell lung cancer. During the conference, the effectiveness of immune checkpoint inhibitors in the long-term treatment of this type of cancer was highlighted. Opdivo […]
The Importance of Respiratory Rehabilitation Therapy in Lung Cancer Treatment
Respiratory Rehabilitation Therapy: An Essential Component of Lung Cancer Treatment The field of lung cancer treatment continues to expand with the recent approval of Yuhan Corporation’s targeted anti-cancer drug, ‘Rexraza’, as a first-line treatment for non-small cell lung cancer. This, along with the release of other targeted and immune anticancer drugs, emphasizes the growing importance […]
Partnerships between Merck (MSD) and Domestic Bio Pharmaceutical Companies: Examples of Licensing and Clinical Collaboration
Examples of Global Partnerships in the Pharmaceutical Industry Presented at Research Day Event An event was recently held to showcase successful partnerships in the pharmaceutical industry, specifically focused on licensing and clinical collaboration between Merck (MSD), a prominent global pharmaceutical company, and domestic bio-pharmaceutical companies in South Korea. Merck’s Licensing Partnership with Hanmi Pharm During […]
Improving Access to Keytruda: Expanding Reimbursement for Unmet Cancer Indications
Improving Access to Unmet Demand: Keytruda to Receive Reimbursement for Additional Cancer Indications Immuno-oncology drug, Keytruda, is set to receive reimbursement for high unmet demand indications. This groundbreaking medication has already obtained coverage for seven indications across four types of carcinoma. Now, it aims to tackle △early triple-negative breast cancer, △metastatic or recurrent triple breast […]
Is a cancer vaccine commercially available?
Image Source: Getty Image Bank [메디칼업저버 양영구 기자] The commercialization of the ‘cancer vaccine’ being developed by the global pharmaceutical industry is getting closer. Currently, cervical cancer is the only vaccine that can prevent cancer. Cervical cancer is caused by human papillomavirus (HPV) infection, so targeting it can prevent cancer. However, since vaccines are innately […]
Drugs to be developed in virtual space… “I need to come up with an in silico strategy”
Prepare a forum for the exchange of views on patents, the core of the pharmaceutical industry, including strategies to protect the patent rights of ‘Humira’ and ‘Keytruda’, which compete for the main global pharmaceutical sales, and prepare a patent system for development drugs with digital and artificial intelligence (AI) technology in the future is done. […]
